In 1968 was created Dexcel Pharma, which is appeared as Corporate Investor. The venture was found in Asia in Israel. The leading representative office of defined Corporate Investor is situated in the Jerusalem.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Dexcel Pharma, startups are often financed by Viking Global Investors, SoftBank Investment Advisers, QVT Financial. The meaningful sponsors for the fund in investment in the same round are QVT Financial, Viking Global Investors, SoftBank Investment Advisers. In the next rounds fund is usually obtained by Viking Global Investors, SoftBank Investment Advisers, Founders Fund.
The fund was created by Dan Oren. The overall number of key employees were 1.
For fund there is no match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular fund investment industries, there are Biopharma, Health Care. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Roivant Sciences
Deals in the range of more than 100 millions dollars are the general things for fund. The fund is generally included in less than 2 deals every year. When the investment is from Dexcel Pharma the average startup value is more than 1 billion dollars. The important activity for fund was in 2014.
| Fund Name | Location |
| Burch Investment Group | Nashville, Tennessee, United States |
| Digital Ventures | Australia, Perth, Western Australia |
| DragonVenture | California, Menlo Park, United States |
| Endeavour Investment Partners | Hingham, Massachusetts, United States |
| Gibraltar Business Capital | Illinois, Northbrook, United States |
| Holdinvest | Argentina, Buenos Aires, Distrito Federal |
| ICB | - |
| Jiasufei Keji | Beijing, China, Haidian |
| Mingyao Guquan Touzi | China, Shanghai |
| New Harbor Capital | Chicago, Illinois, United States |
| Olympus Partners | Connecticut, Stamford, United States |
| Pioneering Ventures | Switzerland, Zürich, Zurich |
| Shapeways | New York, New York, United States |
| Sistema SmartTech | - |
| Sukna Ventures | Ar Riyad, Riyadh, Saudi Arabia |
| Sunner Capital | - |
| Upstart Labs | Oregon, Portland, United States |
| Visionary Venture Fund | Aliso Viejo, California, United States |
| Visma | Norway, Oslo |
| Z-kai | Japan, Shizuoka, Shizuoka Prefecture |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States | ||
Immunai | $60M | 11 Feb 2021 | New York, United States | ||
Kriya Therapeutics | $80M | 12 May 2020 | Palo Alto, California, United States |
– Israeli stroke therapy technology startup, BrainQ, today announced a $40m funding round led by Hanaco Ventures, along with Dexcel Pharma, and Peregrine Ventures.
– The funding will be used to support a multicenter pivotal trial for its groundbreaking technology for ischemic stroke survivors in selected US hospitals.
– This year, BrainQ received FDA Breakthrough Device Designation allowing the company to work closely with the FDA to expedite development plans and premarket clearance, with access to the new Medicare Coverage of Innovative Technology pathway.
– Kriya closed a $100m Series B financing to support its mission of transforming the design, development and manufacturing of gene therapies.
– The financing was led by Patient Square Capital with participation from new investors Woodline Partners LP, CAM Capital, Hongkou, Alumni Ventures and others.
– All existing institutional investors also participated in this round, including QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures, Transhuman Capital, Narya Capital, Amplo and JDRF T1D Fund.
– Proceeds from the financing will be used to further develop Kriya’s core technology platforms, expand its therapeutic pipeline and advance its current programs in metabolic disease, ophthalmology and oncology.
– Jim Momtazee, Managing Partner of Patient Square Capital, will join Kriya’s Board of Directors.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Kriya Therapeutics | $270M | 16 May 2022 | Palo Alto, California, United States | ||
Kriya Therapeutics | $100M | 14 Jul 2021 | Palo Alto, California, United States | ||
Immunai | $60M | 11 Feb 2021 | New York, United States | ||
Kriya Therapeutics | $80M | 12 May 2020 | Palo Alto, California, United States |
